These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37908001)

  • 1. Trends in teicoplanin loading dose implementation from 2010 to 2019 and evaluation of safety and efficacy factors: a retrospective cohort study based on a Japanese administrative claims database.
    Goto R; Muraki Y; Inose R; Ichii M; Sawada K; Mizuno K; Koizumi R; Tsuzuki S; Ishikane M; Ohmagari N
    J Pharm Health Care Sci; 2023 Nov; 9(1):35. PubMed ID: 37908001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of the ward pharmacy service with active implementation of therapeutic drug monitoring for vancomycin and teicoplanin-an epidemiological surveillance study using Japanese large health insurance claims database.
    Imai S; Momo K; Kashiwagi H; Miyai T; Sugawara M; Takekuma Y
    J Pharm Health Care Sci; 2020; 6():18. PubMed ID: 32832095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Change of teicoplanin loading dose requirement for incremental increases of systemic inflammatory response syndrome score in the setting of sepsis.
    Nakano T; Nakamura Y; Takata T; Irie K; Sano K; Imakyure O; Mishima K; Futagami K
    Int J Clin Pharm; 2016 Aug; 38(4):908-14. PubMed ID: 27125378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a teicoplanin loading regimen that rapidly achieves target serum concentrations in critically ill patients with severe infections.
    Nakamura A; Takasu O; Sakai Y; Sakamoto T; Yamashita N; Mori S; Morita T; Nabeta M; Hirayu N; Yoshiyama N; Moroki M; Tashiro K; Kannae M
    J Infect Chemother; 2015 Jun; 21(6):449-55. PubMed ID: 25726436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of pharmacists and infection control teams or antimicrobial stewardship teams on the safety and efficacy of vancomycin: A Japanese administrative claims database study.
    Goto R; Muraki Y; Inose R; Kusama Y; Ono A; Koizumi R; Ishikane M; Ohmagari N
    PLoS One; 2022; 17(9):e0274324. PubMed ID: 36083990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of trends and factors associated with therapeutic drug monitoring (TDM) implementation for arbekacin treatment using a large Japanese medical claims database.
    Ito S; Goto R; Inose R; Kusama Y; Ono A; Koizumi R; Ishikane M; Ohmagari N; Muraki Y
    J Infect Chemother; 2022 Sep; 28(9):1266-1272. PubMed ID: 35606308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of acute kidney injury after teicoplanin- or vancomycin- and piperacillin/tazobactam combination therapy: A comparative study using propensity score matching analysis.
    Sazanami K; Inose R; Yagi T; Dote S; Horiuchi N; Kobayashi Y; Muraki Y
    J Infect Chemother; 2021 Dec; 27(12):1723-1728. PubMed ID: 34446352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Possibility of Poor Outcomes after Treatment Using Teicoplanin at the Minimum Inhibitory Concentration of >2 μg/mL in Methicillin-resistant Staphylococcus aureus Bacteremia].
    Kagami K; Imai S; Tazawa Y; Iwasaki S; Fukumoto T; Akizawa K; Yamada T; Ishiguro N; Iseki K
    Yakugaku Zasshi; 2018; 138(9):1181-1189. PubMed ID: 30175762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simplified chart for determining the initial loading dose of teicoplanin in critically ill patients.
    Yoshida S; Suzuki A; Ohmori T; Niwa T; Okada H; Suzuki K; Kobayashi R; Doi T; Kitaichi K; Matsuura K; Murakami N; Ogura S; Itoh Y
    Pharmazie; 2017 Jan; 72(1):53-57. PubMed ID: 29441898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Necessity of personalized initial loading dose calculation of teicoplanin by clinical pharmacist-examination of the utility of using systemic inflammatory response syndrome score-].
    Nakano T; Nakamura Y; Togawa A; Takata T; Ishikura H; Mishima K; Futagami K
    Yakugaku Zasshi; 2014; 134(12):1367-73. PubMed ID: 25452245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibacterial effects of brand-name teicoplanin and generic products against clinical isolates of methicillin-resistant Staphylococcus aureus.
    Fujimura S; Fuse K; Takane H; Nakano Y; Gomi K; Kikuchi T; Watanabe A
    J Infect Chemother; 2011 Feb; 17(1):30-3. PubMed ID: 20665064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of teicoplanin concentrations and safety analysis in neonates.
    Yamada T; Kubota T; Nakamura M; Ochiai M; Yonezawa M; Yano T; Kawashiri T; Egashira N; Hara T; Masuda S
    Int J Antimicrob Agents; 2014 Nov; 44(5):458-62. PubMed ID: 25218156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal teicoplanin loading regimen to rapidly achieve target trough plasma concentration in critically ill patients.
    Li H; Gao L; Zhou L; Wang Y; Li Q; Wang J; Chen T; Zhang Y; Wang T; Shi Q
    Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):277-288. PubMed ID: 31608579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in the pharmacokinetics of teicoplanin in patients with hyperglycaemic hypoalbuminaemia: Impact of albumin glycosylation on the binding of teicoplanin to albumin.
    Enokiya T; Muraki Y; Iwamoto T; Okuda M
    Int J Antimicrob Agents; 2015 Aug; 46(2):164-8. PubMed ID: 25982916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate-severe Gram-positive infections.
    Zhou L; Gao Y; Cao W; Liu J; Guan H; Zhang H; Shi Y; Lv W; Cheng L
    Infect Drug Resist; 2018; 11():29-36. PubMed ID: 29379306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of teicoplanin dosing designs to achieve a new target trough concentration.
    Ueda T; Takesue Y; Nakajima K; Ichki K; Wada Y; Tsuchida T; Takahashi Y; Ishihara M; Tatsumi S; Kimura T; Ikeuchi H; Uchino M
    J Infect Chemother; 2012 Jun; 18(3):296-302. PubMed ID: 22065089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of Teicoplanin on the PT-INR Controlled by Warfarin in Infection Patients].
    Nakano T; Nakamura T; Nakamura Y; Irie K; Sato K; Matsuo K; Imakyure O; Ogata K; Mishima K; Kamimura H
    Yakugaku Zasshi; 2017; 137(7):909-916. PubMed ID: 28674307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level.
    Sato M; Chida K; Suda T; Muramatsu H; Suzuki Y; Hashimoto H; Gemma H; Nakamura H
    J Infect Chemother; 2006 Aug; 12(4):185-9. PubMed ID: 16944256
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.